Announcements
- Applied Therapeutics Reports First Quarter 2024 Financial Results
- Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
- Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
- Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
- Applied Therapeutics Announces $100 Million Private Placement
- Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
- Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
More ▼
Key statistics
As of last trade, Applied Therapeutics Inc (2UV:FRA) traded at 3.66, 218.06% above the 52 week low of 1.15 set on Sep 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.66 |
---|---|
High | 3.66 |
Low | 3.66 |
Bid | 3.68 |
Offer | 3.79 |
Previous close | 3.72 |
Average volume | 16.67 |
---|---|
Shares outstanding | 114.27m |
Free float | 107.65m |
P/E (TTM) | -- |
Market cap | 461.64m USD |
EPS (TTM) | -1.91 USD |
Data delayed at least 15 minutes, as of May 24 2024 08:59 BST.
More ▼